Max S. Topp

Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia

Hagop Kantarjian, Anthony S. Stein, Nicola Gökbuget et al. · New England Journal of Medicine · 2017 · 2K citations · Full text

Targeted Therapy With the T-Cell–Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival

Max S. Topp, Peter Kufer, Nicola Gökbuget et al. · Journal of Clinical Oncology · 2011 · 902 citations · Full text

Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial

Andreas Engert, Heinz Haverkamp, Carsten Kobe et al. · The Lancet · 2012 · 621 citations

Lymphoid Neoplasia, Radiation Therapy, Medicine +6

A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma

Achim Rothe, Stephanie Sasse, Max S. Topp et al. · Blood · 2015 · 320 citations · Full text

Dose-Intensification in Early Unfavorable Hodgkin's Lymphoma: Final Analysis of the German Hodgkin Study Group HD14 Trial

Bastian von Tresckow, Annette Plütschow, Michael Fuchs et al. · Journal of Clinical Oncology · 2012 · 311 citations · Full text